Erdanat 4 mg Erdanat 4 mg contains erdafitinib, a prescription medicine used to treat certain types of advanced or metastatic bladder and urinary tract cancer with specific FGFR gene alterations. It belongs to a group of targeted cancer therapies that work by blocking abnormal signals responsible for cancer cell growth, helping to slow the spread of the disease.

Effects & Benefits Helps slow the growth and spread of cancer cells with FGFR gene alterations. Supports the treatment of advanced urothelial cancer. Targets specific cancer-related pathways while reducing unnecessary effects on healthy cells. May help delay disease progression. Can contribute to better disease management when used under the guidance of an oncology specialist. Possible Side Effects